<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Behav</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2157-9032</journal-id>
<journal-id journal-id-type="publisher-id">BRB3</journal-id>
<journal-title-group>
<journal-title>Brain and Behavior</journal-title>
</journal-title-group>
<issn pub-type="epub">2162-3279</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30307717</article-id>
<article-id pub-id-type="pmc">6236233</article-id>
<article-id pub-id-type="doi">10.1002/brb3.1134</article-id>
<article-id pub-id-type="publisher-id">BRB31134</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>16p11.2 deletion in patients with paroxysmal kinesigenic dyskinesia but without intellectual disability</article-title>
<alt-title alt-title-type="left-running-head">LI et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="brb31134-cr-0001">
<name>
<surname>Li</surname>
<given-names>Wen</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="brb31134-note-1001">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0002">
<name>
<surname>Wang</surname>
<given-names>Yifan</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="brb31134-note-1001">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0003">
<name>
<surname>Li</surname>
<given-names>Bin</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0004">
<name>
<surname>Tang</surname>
<given-names>Bin</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0005">
<name>
<surname>Sun</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0006">
<name>
<surname>Lai</surname>
<given-names>Jinxing</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0007">
<name>
<surname>He</surname>
<given-names>Na</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0008">
<name>
<surname>Li</surname>
<given-names>Bingmei</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0009">
<name>
<surname>Meng</surname>
<given-names>Heng</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb31134-cr-0010">
<name>
<surname>Liao</surname>
<given-names>Weiping</given-names>
</name>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="brb31134-cr-0011">
<name>
<surname>Liu</surname>
<given-names>Xiaorong</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7769-9564</contrib-id>
<address>
<email>happyxiaorongo@163.com</email>
</address>
<xref ref-type="aff" rid="brb31134-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb31134-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="brb31134-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Institute of Neuroscience</named-content>
<institution>the Second Affiliated Hospital of Guangzhou Medical University</institution>
<named-content content-type="city">Guangzhou</named-content>
<country country="CN">China</country>
</aff>
<aff id="brb31134-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province</named-content>
<institution>the Ministry of Education of China</institution>
<named-content content-type="city">Guangzhou</named-content>
<country country="CN">China</country>
</aff>
<aff id="brb31134-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Neurology, the First Affiliated Hospital and Clinical Neuroscience Institute</named-content>
<institution>Jinan University</institution>
<named-content content-type="city">Guangzhou</named-content>
<country country="CN">China</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Xiaorong Liu, Institute of Neuroscience, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.<break></break>
Email: <email>happyxiaorongo@163.com</email><break></break></corresp>
<fn id="brb31134-note-1001">
<label>†</label>
<p>These authors are co‐first authors due to their equal contribution to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>11</month>
<year>2018</year>
</pub-date>
<volume>8</volume>
<issue>11</issue>
<issue-id pub-id-type="doi">10.1002/brb3.2018.8.issue-11</issue-id>
<elocation-id>e01134</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 Published by Wiley Periodicals, Inc. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. <italic>Brain and Behavior</italic> published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BRB3-8-e01134.pdf" xlink:type="simple"></self-uri>
<abstract id="brb31134-abs-0001">
<title>Abstract</title>
<sec id="brb31134-sec-0001">
<title>Introduction</title>
<p>Mutations of the <italic>PRRT2</italic> gene are the most common cause for paroxysmal kinesigenic dyskinesia. However, patients with negative <italic>PRRT2</italic> mutations are not rare. The aim of this study is to determine whether copy number variant of <italic>PRRT2</italic> gene is another potential pathogenic mechanism in the patients with paroxysmal kinesigenic dyskinesia with negative<italic> PRRT2</italic> point and frameshift mutations.</p>
</sec>
<sec id="brb31134-sec-0002">
<title>Methods</title>
<p>We screened <italic>PRRT2</italic> copy number variants using the AccuCopy™ method in 29 patients with paroxysmal kinesigenic dyskinesia with negative <italic>PRRT2</italic> point and frameshift mutations. Next‐generation sequencing was used to determine the chromosomal deletion sites in patients with <italic>PRRT2</italic> copy number variants, and to exclude mutations in other known causative genes for paroxysmal kinesigenic dyskinesia.</p>
</sec>
<sec id="brb31134-sec-0003">
<title>Results</title>
<p>Two sporadic patients with negative <italic>PRRT2</italic> point and frameshift mutations (6.9%) were identified to have de novo <italic>PRRT2</italic> copy number deletions (591 and 832 Kb deletions located in 16p11.2). The two patients presented with pure paroxysmal kinesigenic dyskinesia and paroxysmal kinesigenic dyskinesia and benign infantile convulsions, respectively. They had normal intelligence and neuropsychiatric development, in contrast to those previously reported with 16p11.2 deletions complicated with neuropsychiatric disorders. No correlation between the deletion ranges and phenotypic variations was found.</p>
</sec>
<sec id="brb31134-sec-0004">
<title>Conclusion</title>
<p>16p11.2 deletions play causative roles in paroxysmal kinesigenic dyskinesia, especially for sporadic cases. Our findings extend the phenotype of 16p11.2 deletions to pure paroxysmal kinesigenic dyskinesia. Screening for 16p11.2 deletions should thus be included in genetic evaluations for patients with paroxysmal kinesigenic dyskinesia.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="brb31134-kwd-0001">16p11.2 deletion</kwd>
<kwd id="brb31134-kwd-0002">copy number variants</kwd>
<kwd id="brb31134-kwd-0003">paroxysmal kinesigenic dyskinesia</kwd>
<kwd id="brb31134-kwd-0004"><italic>PRRT2</italic> gene</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Key Research Project of the Ministry of Science and Technology of China</funding-source>
<award-id>2016YFC0904400</award-id>
</award-group>
<award-group>
<funding-source>National Natural Science Foundation of China</funding-source>
<award-id>81571273</award-id>
<award-id>81871015</award-id>
</award-group>
<award-group>
<funding-source>Guangdong Provincial Department of Education</funding-source>
<award-id>2012KJCX009</award-id>
</award-group>
<award-group>
<funding-source>Science and Information Technology Bureau of Guangzhou</funding-source>
<award-id>2014J4100062</award-id>
<award-id>201508020011</award-id>
<award-id>201607010002</award-id>
</award-group>
<award-group>
<funding-source>Natural Science Foundation of Guangdong Province</funding-source>
<award-id>2014A030313489</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="0"></table-count>
<page-count count="7"></page-count>
<word-count count="11559"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>brb31134</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>November 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.1 mode:remove_FC converted:15.11.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="brb31134-cit-1001" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>16p11.2 deletion in patients with paroxysmal kinesigenic dyskinesia but without intellectual disability</article-title>. <source xml:lang="en"/>Brain Behav. <year>2018</year>;<volume>8</volume>:<elocation-id>e01134</elocation-id>
<pub-id pub-id-type="doi">10.1002/brb3.1134</pub-id>
</mixed-citation>
</p>
</notes>
</front>
<body>
<sec id="brb31134-sec-0005">
<label>1</label>
<title>INTRODUCTION</title>
<p>Paroxysmal kinesigenic dyskinesia (PKD) is an autosomal dominant inheritance disorder characterized by paroxysmal involuntary dystonic, choreoathetoid, and ballistic attacks triggered by sudden movements (Jankovic &amp; Demirkiran,<xref ref-type="ref" rid="brb31134-bib-0014">2002</xref>). It has been demonstrated to be associated with mutations in several genes, including <italic>PRRT2</italic> (proline‐rich region transmembrane protein‐2) (Chen et al., <xref ref-type="ref" rid="brb31134-bib-0003">2011</xref>), <italic> SLC2A1</italic> (solute carrier family 2, member 1), <italic>MR‐1</italic> (myofibrillogenesis regulator 1), <italic>CLCN1</italic> (chloride voltage‐gated channel 1) (Wang, Li, Liu, Wen, &amp; Wu, <xref ref-type="ref" rid="brb31134-bib-0021">2016</xref>), <italic>SCN8A</italic> (sodium voltage‐gated channel alpha subunit 8) (Chen et al., <xref ref-type="ref" rid="brb31134-bib-0004">2015</xref>), and<italic> ADCY5</italic> (adenylyl cyclase 5) (Gardella et al., <xref ref-type="ref" rid="brb31134-bib-0011">2016</xref>). <italic>PRRT2</italic> is the most common known causative gene for PKD. Point and frameshift mutations in <italic>PRRT2</italic> account for 20.8%–48.4% of cases with PKD (Huang et al., <xref ref-type="ref" rid="brb31134-bib-0013">2015</xref>; Liu et al., <xref ref-type="ref" rid="brb31134-bib-0017">2013</xref>; Youn et al., <xref ref-type="ref" rid="brb31134-bib-0025">2014</xref>). Clinically, PKD cases with negative genetic findings are not rare, especially the sporadic cases (Wang et al., <xref ref-type="ref" rid="brb31134-bib-0021">2016</xref>). Since the majority of <italic>PRRT2</italic> mutations are truncating mutations that lead to loss of function or haploinsufficiency of <italic>PRRT2,</italic> copy number deletions of this gene are suspected to cause PKD.</p>
<p>In the present study, we examined copy number variants (CNVs) of <italic>PRRT2</italic> in patients with PKD with negative point and frameshift mutations in <italic>PRRT2</italic> using the AccuCopy™ method. Further, next‐generation sequencing (NGS) was performed to determine the range of deletions and exclude abnormalities in other known causative genes for PKD in patients with <italic>PRRT2</italic> CNVs.</p>
</sec>
<sec id="brb31134-sec-0006">
<label>2</label>
<title>METHODS</title>
<sec id="brb31134-sec-0007">
<label>2.1</label>
<title>Participants</title>
<p>Twenty‐nine PKD patients with negative <italic>PRRT2</italic> point and frameshift mutations, 13 PKD patients with <italic>PRRT2</italic> point or frameshift mutations, and 50 healthy adults were recruited from the Second Affiliated Hospital of Guangzhou Medical University between 2004 and 2016. PKD was diagnosed according to the criteria described by Bruno et al. (<xref ref-type="ref" rid="brb31134-bib-0001">2004</xref>). The clinical data were collected, including semiology and evolution of the disorder, family history, and physical examination results. Video electroencephalography (VEEG) monitoring and brain magnetic resonance imaging were performed to exclude epilepsy and other symptomatic movement disorders.</p>
<p>The ethics committee of the hospital approved the study protocol, and written informed consent was obtained from all participants or their parents.</p>
</sec>
<sec id="brb31134-sec-0008">
<label>2.2</label>
<title>Detection of CNVs of <italic>PRRT2</italic> using the AccuCopy™ method</title>
<p>Blood samples were obtained from the probands, their parents, and other family members when available. Genomic DNA was extracted from peripheral blood using a QuickGene DNA whole blood kit L (Fujifilm, Tokyo, Japan). Mutations in known causative genes for PKD were screened using direct Sanger sequencing or a specific NGS gene panel designed for genes associated with epilepsy and paroxysmal movement disorders. In order to rapidly screen the CNV of <italic>PRRT2</italic> in a large number of patients with a limited amount of sample DNA, an AccuCopy™ multicopy number detection method (Genesky Bio‐Tech Co., Ltd., Shanghai, China) was used. Twenty‐nine patients with negative <italic>PRRT2</italic> point and frameshift mutation (P1‐P29) were screened for <italic>PRRT2</italic> CNVs. Thirteen patients with <italic>PRRT2</italic> missense or truncation mutations (PC1‐PC13) and 50 healthy adults (C1‐C50) were also screened as positive controls and healthy controls, respectively.</p>
<p>The basic principle of AccuCopy™ multicopy number detection has been described previously (Du et al., <xref ref-type="ref" rid="brb31134-bib-0007">2012</xref>). Five probes were designed to cover the region spanning the 5′‐UTR to 3′‐UTR untranslated region of <italic>PRRT2</italic>. The probe primers are listed in the Supporting Information Table <xref ref-type="supplementary-material" rid="brb31134-sup-0001">S1</xref>. Three reference genes (<italic>POP1</italic>,<italic> RPP14</italic>, and<italic> TBX15</italic>) were utilized for normalization. AccuCopy™ was performed according to the manufacturer’s instructions. Raw data were analyzed using GeneMapper 4.0. The sample/competitive peak ratio for each target fragment was first normalized three times to three reference genes and then averaged. The copy number of each target fragment was calculated using the average sample/competitive ratio. Parental DNA from the patients with <italic>PRRT2</italic> CNVs was used to determine the origins of the gene variants.</p>
</sec>
<sec id="brb31134-sec-0009">
<label>2.3</label>
<title>Whole genome CNV analysis using high‐throughput NGS in patients with <italic>PRRT2</italic> CNVs</title>
<p>In order to determine the locations of the deletions, high‐throughput whole genome NGS was carried out in patients with CNVs of <italic>PRRT2</italic> by MyGenostics Inc. (Beijing, China). Qualified genomic DNA samples were randomly fragmented into fragments of 100–700 bp and adapters were ligated to both ends of the fragments. The DNA strands were separated into single strands. Strict quality control testing using Nanodrop 2000 (Thermo Fisher Scientific, DE) and quantitative polymerase chain reaction were performed during the entire process of library construction. Each captured library was loaded onto an Illumina HiSeq X10 platform to perform high‐throughput sequencing using paired‐end 150 base‐pair reads. The bioinformatics analysis was performed to utilize sequencing data generated from the complete genomics sequencing platform. The base‐calling software received data from the imager after each reaction cycle to form raw read data. BWA‐SW was used to perform the alignment. Regions of the genome deemed likely to differ from the reference genome were identified using the alignment data. All detected CNVs were compared to known CNVs in publicly available databases, including OMIM (<ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link>, RRID: <ext-link ext-link-type="uri" xlink:href="http://scicrunch.org/resolver/SCR_006437">http://scicrunch.org/resolver/SCR_006437</ext-link>), GeneReviews (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link>20301295, RRID: <ext-link ext-link-type="uri" xlink:href="http://scicrunch.org/resolver/SCR_006560">http://scicrunch.org/resolver/SCR_006560</ext-link>), Decipher (<ext-link ext-link-type="uri" xlink:href="https://decipher.sanger.ac.uk/">https://decipher.sanger.ac.uk/</ext-link>, RRID: <ext-link ext-link-type="uri" xlink:href="http://scicrunch.org/resolver/SCR_006552">http://scicrunch.org/resolver/SCR_006552</ext-link>), ClinVar (<ext-link ext-link-type="uri" xlink:href="https://www.clinicalgenome.org/data-sharing/clinvar/">https://www.clinicalgenome.org/data-sharing/clinvar/</ext-link>, RRID: <ext-link ext-link-type="uri" xlink:href="http://scicrunch.org/resolver/SCR_006169">http://scicrunch.org/resolver/SCR_006169</ext-link>), and DGV (<ext-link ext-link-type="uri" xlink:href="https://dgv.tcag.ca/dgv/app/home">https://dgv.tcag.ca/dgv/app/home</ext-link>, RRID: <ext-link ext-link-type="uri" xlink:href="http://scicrunch.org/resolver/SCR_007000">http://scicrunch.org/resolver/SCR_007000</ext-link>).</p>
</sec>
<sec id="brb31134-sec-0010">
<label>2.4</label>
<title>A literature review for PKD patients with 16p11.2 deletions</title>
<p>To explore the genotype‐phenotype association, 16p11.2 deletions with the phenotype of PKD and related phenotypes were systematically retrieved from the PubMed database till December 2017.</p>
</sec>
</sec>
<sec id="brb31134-sec-0011">
<label>3</label>
<title>RESULTS</title>
<sec id="brb31134-sec-0012">
<label>3.1</label>
<title>CNVs of <italic>PRRT2</italic>
</title>
<p>
<italic>PRRT2</italic> CNVs were analyzed in 29 patients with negative point and frameshift mutations, 13 patients with point and frameshift mutations, and 50 healthy controls. Reduced amplification of target segments (<italic>PRRT2</italic> S1–S5) was found in two (6.9%) patients with negative <italic>PRRT2</italic> point and frameshift mutations (patients P3 and P15), implying that one copy of the whole <italic>PRRT2</italic> gene was deleted. No copy number deletion or duplication of <italic>PRRT2</italic> was found in the rest of the subjects (Figure <xref ref-type="fig" rid="brb31134-fig-0001">1</xref>).</p>
<fig fig-type="Figure" id="brb31134-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Copy number deletions of <italic>PRRT2</italic> in two patients with PKD detected using AccuCopy™. The copy number of <italic>PRRT2</italic> was determined based on the copy numbers of five target segments (<italic>PRRT2</italic> S1–S5). One copy deletions of segment S1–S5 were identified in patients P3 and P15, indexed by red bars. Black bars represent PKD patients with negative <italic>PRRT2</italic> point and frameshift mutations (P1–P29), light gray bars represent healthy controls (C1–C50), and dark gray bars represent positive controls (PC1–PC13)</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="BRB3-8-e01134-g001"></graphic>
</fig>
<p>No copy number deletion was found in the parents of patients P3 and P15 (Figure <xref ref-type="fig" rid="brb31134-fig-0002">2</xref>), indicating that the deletions in the two patients were de novo.</p>
<fig fig-type="Figure" id="brb31134-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>The pedigree of the patients with 16p11.2 deletions. (a) Pedigree of patient P3 who presented with PKD. (b) Pedigree of patient P15 who presented with PKD and benign infantile convulsions. <italic>N</italic> indicates normal copy numbers. NA indicates not available</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="BRB3-8-e01134-g002"></graphic>
</fig>
<p>The ranges of the deletions in patients P3 and P15 were further investigated using NGS. Patient P3 had a 591 kb deletion in chromosome 16 [arr16p11.2 (29615090–30207087) × 1] (Figure <xref ref-type="fig" rid="brb31134-fig-0003">3</xref>), which encompassed 37 genes and transcripts, including five Mendelian disease genes (<italic>PRRT2</italic>,<italic> KIF22</italic>,<italic> ALDOA</italic>,<italic> TBX6</italic>, and <italic>CORO1A</italic>). This patient also had a 137 kb deletion in chromosome 2 [arr2p13.2 (72751634–72888731) × 1], which encompassed a part of the <italic>EXOC6B</italic> gene. Patient P15 only had an 832 kb deletion on chromosome 16 [arr16p11.2 (29494072–30326832) × 1], which encompassed 45 genes and transcripts, including the five Mendelian disease genes described above (Figure <xref ref-type="fig" rid="brb31134-fig-0003">3</xref>). Of the affected genes, <italic>KIF22</italic> and <italic>TBX6</italic> are not expressed in the brain; thus, their pathogenic roles for PKD were excluded. <italic>CORO1A</italic> is associated with immunodeficiency 8, <italic>ALDOA</italic> is associated with glycogen storage disease 12 and ataxia‐telangiectasia‐like disorder 2, and<italic> EXOC6B</italic> is associated with intellectual disability and developmental delay. No evidence currently suggests that these genes are related to PKD. <italic>PRRT2</italic> is the only known causative gene for PKD in this region.</p>
<fig fig-type="Figure" id="brb31134-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Genomic positions of the deletions and phenotypes of the PKD patients with 16p11.2 deletions. Genomic positions of the 16p11.2 deletions in patients with PKD are shown using red bars. Bright red bars indicate the 16p11.2 deletions in the present study. Light red bars indicate the deletions reported in the literature. Their corresponding phenotypes are listed on the right. The involved genes are produced using the Ensemble Genome Browser (<ext-link ext-link-type="uri" xlink:href="https://grch37.ensembl.org/Homo_sapiens/Location">https://grch37.ensembl.org/Homo_sapiens/Location</ext-link>) and listed below the bars. The morbid genes are indexed using black fonts. The haploinsufficiency scores of the involved genes are produced using the DECIPHER database (<ext-link ext-link-type="uri" xlink:href="https://decipher.sanger.ac.uk/">https://decipher.sanger.ac.uk/</ext-link>) and indexed by colored fonts. DD: developmental delay; EP: epilepsy; ID: intellectual disability; PKD: paroxysmal kinesigenic dyskinesia; SD: speech delay</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="BRB3-8-e01134-g003"></graphic>
</fig>
<p>No mutations in other known causative genes for PKD (including <italic>MR‐1</italic>,<italic> SLC2A1</italic>,<italic> CLCN1</italic>,<italic> SCN8A,</italic> and<italic> ADCY5</italic>) were found in patients P3 and P15 using the NGS gene panel.</p>
</sec>
<sec id="brb31134-sec-0013">
<label>3.2</label>
<title>Clinical features of the two patients with CNVs of<italic> PRRT2</italic>
</title>
<p>Patient P3 was a 17‐year‐old male with normal development and negative family history of PKD and epilepsy. He had his first dystonic attack at 11 years of age. The attack manifested as twitching in the upper limbs and facial muscles when suddenly standing up, accompanied by clasping of all five fingers without loss of consciousness. This lasted for more than 10 s. Since then, the attacks have occurred about 3–4 times per month and are usually exacerbated by sleep deprivation. The patient had no history of febrile seizures or epileptic attacks. Normal VEEG was recorded at the age of eleven. The patient was diagnosed with PKD. The attacks did not respond to valproate acid (VPA; 15 mg kg<sup>−1</sup> day<sup>−1</sup>) initially, but were controlled by carbamazepine (0.3 g/day) later. The patient had normal intelligence and graduated from a normal senior middle school with average performance. No language disability and autistic features were found (Figure <xref ref-type="fig" rid="brb31134-fig-0002">2</xref>a).</p>
<p>Patient P15 was a 22‐year‐old female with negative family history of febrile seizures, epilepsy, and paroxysmal dyskinesia. The patient was normally delivered. Her early childhood development was normal. She presented with epileptic seizures beginning at the age of 8 months with a frequency interval of 2–3 days. She became seizure free for 5 years while being treated with VPA (20 mg kg<sup>−1</sup> day<sup>−1</sup>), which was withdrawn later. Since the age of 13 years, she presented with uncontrollable choreoathetoid movements of the extremities with awareness when she suddenly changed positions during the daytime. The attacks usually lasted for 2–3 s with a frequency of 6–8 times per month. Her body weight was gradually increased. The body mass index increased from 19.5 at age 12–29.3 at age 22. Neurological examination findings were normal. No speech abnormalities or autistic features were observed. The intelligence test is normal by Wechsler Adult Intelligence Scale at the age of 20 years (IQ = 96). VEEG monitoring showed irregular medium voltage slowing in the right temporal region. No epileptiform discharge was recorded. The patient was diagnosed with PKD and benign infantile convulsions. The PKD attacks were controlled by oxcarbazepine (450 mg/day; Figure <xref ref-type="fig" rid="brb31134-fig-0002">2</xref>b).</p>
</sec>
<sec id="brb31134-sec-0014">
<label>3.3</label>
<title>Phenotypes and genotypes in PKD patients with 16p11.2 deletions</title>
<p>To date, more than 400 patients with 16p11.2 deletions have been reported. Only six of these cases have been reported to have PKD (Dale, Grattan‐Smith, Fung, &amp; Peters, <xref ref-type="ref" rid="brb31134-bib-0005">2011</xref>; Dale, Grattan‐Smith, Nicholson, &amp; Peters, <xref ref-type="ref" rid="brb31134-bib-0006">2012</xref>; Lipton &amp; Rivkin, <xref ref-type="ref" rid="brb31134-bib-0016">2009</xref>; Silveira‐Moriyama et al., <xref ref-type="ref" rid="brb31134-bib-0019">2013</xref>; Termsarasab et al., <xref ref-type="ref" rid="brb31134-bib-0020">2014</xref>; Weber, Kohler, Hahn, Neubauer, &amp; Muller, <xref ref-type="ref" rid="brb31134-bib-0022">2013</xref>). The deletion ranges and phenotypes of these patients with PKD are summarized in Figure <xref ref-type="fig" rid="brb31134-fig-0003">3</xref>. Speech delay was found in five patients, intellectual disability was presented in four, and epilepsy was found in three. Autism, orobuccal dyspraxia, developmental delay, ataxia, parkinsonism, tics, and dysmorphism were observed in one patient each. In contrast, the two patients in this study presented with pure PKD or PKD and benign infantile convulsions, but without any other psychological or neurological symptoms. The ranges of the deletions in the eight patients with PKD covered a large region of 903,843 bp (from 29303244 to 30207087). This range includes 34 genes encoding proteins, seven RNA genes, and four pseudogenes. The overlapping range is a 398,398 bp segment from 29615090 to 30013488 and contains 18 encoding genes. Of these genes, only two are known causative ones—<italic>PRRT2</italic> and <italic>KIF22</italic>. <italic>PRRT2</italic> is the gene responsible for the phenotype of PKD. In the range of deletions, no specific gene was found to explain the phenotypes of speech delay and intellectual disability.</p>
</sec>
</sec>
<sec id="brb31134-sec-0015">
<label>4</label>
<title>DISCUSSION</title>
<p>Paroxysmal kinesigenic dyskinesia is an autosomal chromosome dominant heredity disorder with obvious heterogeneity of phenotypes and genotypes. <italic>PRRT2</italic> is the most common causative gene for PKD. Mutations of <italic>PRRT2</italic>, including point mutations and frameshift mutations, explain approximately less than one‐half of PKD cases (Huang et al., <xref ref-type="ref" rid="brb31134-bib-0013">2015</xref>), suggesting the presence of additional molecular pathogenic mechanisms. In this study, <italic>PRRT2</italic> CNVs were identified in two patients with PKD, indicating that copy number deletion of <italic>PRRT2</italic> is also a potential pathogenic factor for the disease.</p>
<p>In previous studies, point and frameshift mutations in <italic>PRRT2</italic> were identified in 61.5%–100% of familial cases of PKD (Huang et al., <xref ref-type="ref" rid="brb31134-bib-0013">2015</xref>; Liu et al., <xref ref-type="ref" rid="brb31134-bib-0017">2013</xref>). Even in sporadic cases, the majority point and frameshift mutations of <italic>PRRT2</italic> were inherited from unaffected parents (Ebrahimi‐Fakhari, Saffari, Westenberger, &amp; Klein, <xref ref-type="ref" rid="brb31134-bib-0009">2015</xref>). In contrast, the two mutations in this study were de novo. It indicates that screening for <italic>PRRT2</italic> CNV is necessary in patients with PKD, especially in sporadic cases.</p>
<p>In this study, the deletions in the two patients with PKD were beyond the range of the <italic>PRRT2</italic> gene (chr16: 29812087–29815881) and were similar to the range of mutations in chromosome 16p11.2 deletion syndrome. Chromosome 16p11.2 deletion syndrome is a genetic disorder associated with multiple system abnormalities, including intellectual impairment, developmental disorders, psychical and psychological disease, motor hypotonia, seizures, obesity, immune deficiency, syringomyelia, hearing loss, and cardiac defects (Yang et al., <xref ref-type="ref" rid="brb31134-bib-0024">2015</xref>). It is the second common microdeletion disorder (Kaminsky et al., <xref ref-type="ref" rid="brb31134-bib-0015">2011</xref>), occurring in approximately 1 of 10,000 individuals (Weiss et al., <xref ref-type="ref" rid="brb31134-bib-0023">2008</xref>) and 0.4%–0.7% of patients with unexplained intellectual disability.(Kaminsky et al., <xref ref-type="ref" rid="brb31134-bib-0015">2011</xref>). Language‐related disorders and intellectual disability are extremely common in patients with 16p11.2 deletion syndrome (Duyzend &amp; Eichler, <xref ref-type="ref" rid="brb31134-bib-0008">2015</xref>; Hanson et al., <xref ref-type="ref" rid="brb31134-bib-0012">2015</xref>; Olson et al., <xref ref-type="ref" rid="brb31134-bib-0018">2014</xref>). Psychiatric and developmental disorders are found in &gt;90% of carriers (Celine &amp; Antony, <xref ref-type="ref" rid="brb31134-bib-0002">2014</xref>). Autistic spectrum disorder is detected in about 18%–25% of deletion carriers (Duyzend &amp; Eichler, <xref ref-type="ref" rid="brb31134-bib-0008">2015</xref>). However, PKD has only been reported in six patients with 16p11.2 deletions, and these cases were simultaneously complicated with other neuropsychiatric abnormalities, including intellectual disability, speech delay, autism, and dysmorphism. In contrast, the two patients in the present study only presented with PKD or PKD and mild epilepsy, which indicates that pure PKD or relatively pure PKD can be a phenotype of 16p11.2 deletion syndrome.</p>
<p>Since 16p11.2 deletion carriers present with obvious phenotypic heterogeneity, it needs to be determined whether the deleted ranges are correlated to the phenotypes. In previous studies, a 593‐kb deletion at map position B29.5–B30.1 Mb in the proximal region of 16p11.2 was defined as a typical 16p11.2 deletion commonly associated with symptoms of brain developmental abnormalities, while a 220‐kb deletion at map position B28.74–B28.95 Mb in the distal region was defined as an atypical 16p11.2 deletion featured by severe obesity due to the involvement of the<italic> SH2B1</italic> gene, which plays a role in leptin and insulin signaling. PKD patients with <italic>PRRT2</italic> CNVs all had the proximal 16p11.2 deletions (Dale et al., <xref ref-type="ref" rid="brb31134-bib-0005">2011</xref>, <xref ref-type="ref" rid="brb31134-bib-0006">2012</xref> ; Lipton &amp; Rivkin, <xref ref-type="ref" rid="brb31134-bib-0016">2009</xref>; Silveira‐Moriyama et al., <xref ref-type="ref" rid="brb31134-bib-0019">2013</xref>; Termsarasab et al., <xref ref-type="ref" rid="brb31134-bib-0020">2014</xref>; Weber et al., <xref ref-type="ref" rid="brb31134-bib-0022">2013</xref>). The overlapping region of the deletions contains two known causative genes—<italic>PRRT2</italic> and <italic>KIF22</italic>. <italic>KIF22</italic> is not expressed in the human brain and is associated with spondyloepimetaphyseal dysplasia with multiple dislocations. Therefore, <italic>PRRT2</italic> is the only responsible gene for the symptoms of PKD in this region. Beyond the overlapping region, three other known causative genes are affected by deletions—<italic>TBX6</italic>,<italic> ALDOA</italic>, and <italic>CORO1A</italic> (Figure <xref ref-type="fig" rid="brb31134-fig-0003">3</xref>). <italic>TBX6</italic> is not expressed in the brain; and no evidence indicates that<italic> ALDOA</italic> and <italic>CORO1A</italic> are related to neuropsychiatric disorders. Thus, these three deleted genes do not explain the symptom variety seen in the central nervous system in such patients. Patient P3 also had a deletion in chromosome 2. This deletion included a part of the gene <italic>EXOC6B</italic>. Although this gene is associated with intellectual disability and developmental delay (Fruhmesser et al., <xref ref-type="ref" rid="brb31134-bib-0010">2013</xref>), patient P3 had clinically normal intelligence and development. Taking together, the molecular basis for the phenotypic variety in PKD patients with 16p11.2 deletions is unknown.</p>
<p>In previous studies, the majority of patients with 16p11.2 deletions had a relatively poor prognosis in intellectual disability, autism, speech delay, and obesity. In contrast, the present study showed that patients with 16p11.2 deletions may present with pure PKD, which had a good response to low‐dose carbamazepine or oxcarbazepine. This finding should be considered in prognostic prediction and genetic counseling for PKD patients. One of the limitations of this study is the limited sample size. Further studies with large cohorts and the functional studies for each involved gene are required to determine the mechanisms underlying the phenotypic diversity of 16p11.2 deletions.</p>
<p>In conclusion, this study identified two de novo 16p11.2 deletions involving <italic>PRRT2</italic> in patients with PKD but without intellectual disability, extending the phenotype of 16p11.2 deletions to typical PKD. Screening for 16p11.2 deletions should be prescribed for patients with PKD, particularly in sporadic cases, although it is not common in the patients with PKD. Further research is required to determine the mechanisms underlying the phenotypic diversity of 16p11.2 deletions.</p>
</sec>
<sec id="brb31134-sec-0017">
<title>CONFLICT OF INTEREST</title>
<p>None declared.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="brb31134-sup-0001">
<caption>
<p> </p>
</caption>
<media xlink:href="BRB3-8-e01134-s001.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="brb31134-sec-0016">
<title>ACKNOWLEDGMENTS</title>
<p>We acknowledge the participants for their kind cooperation. This work was supported by grants from Key Research Project of the Ministry of Science and Technology of China (Omics‐based precision medicine of epilepsy, grant No. 2016YFC0904400), National Natural Science Foundation of China (grant No. 81571273 and 81871015), Guangdong Provincial Department of Education (Grant No. 2012KJCX009), Science and Information Technology Bureau of Guangzhou (Grant No. 2014J4100062, No. 201508020011 and No. 201607010002), Natural Science Foundation of Guangdong Province (Grant No. 2014A030313489).</p>
</ack>
<ref-list content-type="cited-references" id="brb31134-bibl-0001">
<title>REFERENCES</title>
<ref id="brb31134-bib-0001">
<mixed-citation id="brb31134-cit-0001" publication-type="journal">
<string-name>
<surname>Bruno</surname>, <given-names>M. K.</given-names>
</string-name>, <string-name>
<surname>Hallett</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gwinn‐Hardy</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sorensen</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Considine</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Ptacek</surname>, <given-names>L. J.</given-names>
</string-name> (<year>2004</year>). <article-title>Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: New diagnostic criteria</article-title>. <source xml:lang="en"/>Neurology, <volume>63</volume>, <fpage>2280</fpage>–<lpage>2287</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000147298.05983.50</pub-id>.<pub-id pub-id-type="pmid">15623687</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0002">
<mixed-citation id="brb31134-cit-0002" publication-type="journal">
<string-name>
<surname>Celine</surname>, <given-names>T. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Antony</surname>, <given-names>J.</given-names>
</string-name> (<year>2014</year>). <article-title>A study on mental disorders: 5‐year retrospective study</article-title>. <source xml:lang="en"/>Journal of Family Medicine and Primary Care, <volume>3</volume>, <fpage>12</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.4103/2249-4863.130260</pub-id>.</mixed-citation>
</ref>
<ref id="brb31134-bib-0003">
<mixed-citation id="brb31134-cit-0003" publication-type="journal">
<string-name>
<surname>Chen</surname>, <given-names>W. J.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>, <given-names>Z. Q.</given-names>
</string-name>, <string-name>
<surname>Wei</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Ni</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Tan</surname>, <given-names>G. H.</given-names>
</string-name>, … <string-name>
<surname>Wu</surname>, <given-names>Z. Y.</given-names>
</string-name> (<year>2011</year>). <article-title>Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>43</volume>, <fpage>1252</fpage>–<lpage>1255</lpage>. <pub-id pub-id-type="doi">10.1038/ng.1008</pub-id>.<pub-id pub-id-type="pmid">22101681</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0004">
<mixed-citation id="brb31134-cit-0004" publication-type="journal">
<string-name>
<surname>Chen</surname>, <given-names>D. H.</given-names>
</string-name>, <string-name>
<surname>Meneret</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Friedman</surname>, <given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Korvatska</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Gad</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bonkowski</surname>, <given-names>E. S.</given-names>
</string-name>, … <string-name>
<surname>Raskind</surname>, <given-names>W. H.</given-names>
</string-name> (<year>2015</year>). <article-title>ADCY5‐related dyskinesia: Broader spectrum and genotype‐phenotype correlations</article-title>. <source xml:lang="en"/>Neurology, <volume>85</volume>, <fpage>2026</fpage>–<lpage>2035</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000002058</pub-id>.<pub-id pub-id-type="pmid">26537056</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0005">
<mixed-citation id="brb31134-cit-0005" publication-type="journal">
<string-name>
<surname>Dale</surname>, <given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Grattan‐Smith</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Fung</surname>, <given-names>V. S.</given-names>
</string-name>, &amp; <string-name>
<surname>Peters</surname>, <given-names>G. B.</given-names>
</string-name> (<year>2011</year>). <article-title>Infantile convulsions and paroxysmal kinesigenic dyskinesia with 16p11.2 microdeletion</article-title>. <source xml:lang="en"/>Neurology, <volume>77</volume>, <fpage>1401</fpage>–<lpage>1402</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e31823152d7</pub-id>.<pub-id pub-id-type="pmid">21940615</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0006">
<mixed-citation id="brb31134-cit-0006" publication-type="journal">
<string-name>
<surname>Dale</surname>, <given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Grattan‐Smith</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Nicholson</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Peters</surname>, <given-names>G. B.</given-names>
</string-name> (<year>2012</year>). <article-title>Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: A single‐centre study</article-title>. <source xml:lang="en"/>Developmental Medicine and Child Neurology, <volume>54</volume>, <fpage>618</fpage>–<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04287.x</pub-id>.<pub-id pub-id-type="pmid">22515636</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0007">
<mixed-citation id="brb31134-cit-0007" publication-type="journal">
<string-name>
<surname>Du</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>An</surname>, <given-names>H.</given-names>
</string-name>, … <string-name>
<surname>Zhang</surname>, <given-names>F.</given-names>
</string-name> (<year>2012</year>). <article-title>Efficient typing of copy number variations in a segmental duplication‐mediated rearrangement hotspot using multiplex competitive amplification</article-title>. <source xml:lang="en"/>Journal of Human Genetics, <volume>57</volume>, <fpage>545</fpage>–<lpage>551</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2012.66</pub-id>.<pub-id pub-id-type="pmid">22673690</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0008">
<mixed-citation id="brb31134-cit-0008" publication-type="journal">
<string-name>
<surname>Duyzend</surname>, <given-names>M. H.</given-names>
</string-name>, &amp; <string-name>
<surname>Eichler</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2015</year>). <article-title>Genotype‐first analysis of the 16p11.2 deletion defines a new type of "autism"</article-title>. <source xml:lang="en"/>Biological Psychiatry, <volume>77</volume>, <fpage>769</fpage>–<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.02.032</pub-id>.<pub-id pub-id-type="pmid">25843334</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0009">
<mixed-citation id="brb31134-cit-0009" publication-type="journal">
<string-name>
<surname>Ebrahimi‐Fakhari</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Saffari</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Westenberger</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Klein</surname>, <given-names>C.</given-names>
</string-name> (<year>2015</year>). <article-title>The evolving spectrum of PRRT2‐associated paroxysmal diseases</article-title>. <source xml:lang="en"/>Brain, <volume>138</volume>, <fpage>3476</fpage>–<lpage>3495</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awv317</pub-id>.<pub-id pub-id-type="pmid">26598493</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0010">
<mixed-citation id="brb31134-cit-0010" publication-type="journal">
<string-name>
<surname>Fruhmesser</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Blake</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Haberlandt</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Baying</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Raeder</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Runz</surname>, <given-names>H.</given-names>
</string-name>, … <string-name>
<surname>Kotzot</surname>, <given-names>D.</given-names>
</string-name> (<year>2013</year>). <article-title>Disruption of EXOC6B in a patient with developmental delay, epilepsy, and a de novo balanced t(2;8) translocation</article-title>. <source xml:lang="en"/>European Journal of Human Genetics, <volume>21</volume>, <fpage>1177</fpage>–<lpage>1180</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2013.18</pub-id>.<pub-id pub-id-type="pmid">23422942</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0011">
<mixed-citation id="brb31134-cit-0011" publication-type="journal">
<string-name>
<surname>Gardella</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Becker</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Moller</surname>, <given-names>R. S.</given-names>
</string-name>, <string-name>
<surname>Schubert</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lemke</surname>, <given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Larsen</surname>, <given-names>L. H.</given-names>
</string-name>, … <string-name>
<surname>Weber</surname>, <given-names>Y. G.</given-names>
</string-name> (<year>2016</year>). <article-title>Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation</article-title>. <source xml:lang="en"/>Annals of Neurology, <volume>79</volume>, <fpage>428</fpage>–<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24580</pub-id>.<pub-id pub-id-type="pmid">26677014</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0012">
<mixed-citation id="brb31134-cit-0012" publication-type="journal">
<string-name>
<surname>Hanson</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Bernier</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Porche</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>, <given-names>F. I.</given-names>
</string-name>, <string-name>
<surname>Goin‐Kochel</surname>, <given-names>R. P.</given-names>
</string-name>, <string-name>
<surname>Snyder</surname>, <given-names>L. A. G.</given-names>
</string-name>, … <string-name>
<surname>Chung</surname>, <given-names>W. K.</given-names>
</string-name> (<year>2015</year>). <article-title>The cognitive and behavioral phenotype of the 16p11.2 deletion in a clinically ascertained population</article-title>. <source xml:lang="en"/>Biological Psychiatry, <volume>77</volume>, <fpage>785</fpage>–<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.04.021</pub-id>.<pub-id pub-id-type="pmid">25064419</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0013">
<mixed-citation id="brb31134-cit-0013" publication-type="journal">
<string-name>
<surname>Huang</surname>, <given-names>X. J.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>X. L.</given-names>
</string-name>, <string-name>
<surname>Che</surname>, <given-names>X. Q.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Chen</surname>, <given-names>S. D.</given-names>
</string-name> (<year>2015</year>). <article-title>Paroxysmal kinesigenic dyskinesia: Clinical and genetic analyses of 110 patients</article-title>. <source xml:lang="en"/>Neurology, <volume>85</volume>, <fpage>1546</fpage>–<lpage>1553</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000002079</pub-id>.<pub-id pub-id-type="pmid">26446061</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0014">
<mixed-citation id="brb31134-cit-0014" publication-type="journal">
<string-name>
<surname>Jankovic</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Demirkiran</surname>, <given-names>M.</given-names>
</string-name> (<year>2002</year>). <article-title>Classification of paroxysmal dyskinesias and ataxias</article-title>. <source xml:lang="en"/>Advances in Neurology, <volume>89</volume>, <fpage>387</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="pmid">11968463</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0015">
<mixed-citation id="brb31134-cit-0015" publication-type="journal">
<string-name>
<surname>Kaminsky</surname>, <given-names>E. B.</given-names>
</string-name>, <string-name>
<surname>Kaul</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Paschall</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Church</surname>, <given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>Bunke</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Kunig</surname>, <given-names>D.</given-names>
</string-name>, … <string-name>
<surname>Martin</surname>, <given-names>C. L.</given-names>
</string-name> (<year>2011</year>). <article-title>An evidence‐based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>13</volume>, <fpage>777</fpage>–<lpage>784</lpage>. <pub-id pub-id-type="doi">10.1097/GIM.0b013e31822c79f9</pub-id>.<pub-id pub-id-type="pmid">21844811</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0016">
<mixed-citation id="brb31134-cit-0016" publication-type="journal">
<string-name>
<surname>Lipton</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Rivkin</surname>, <given-names>M. J.</given-names>
</string-name> (<year>2009</year>). <article-title>16p11.2‐related paroxysmal kinesigenic dyskinesia and dopa‐responsive parkinsonism in a child</article-title>. <source xml:lang="en"/>Neurology, <volume>73</volume>, <fpage>479</fpage>–<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b16393</pub-id>.<pub-id pub-id-type="pmid">19667324</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0017">
<mixed-citation id="brb31134-cit-0017" publication-type="journal">
<string-name>
<surname>Liu</surname>, <given-names>X. R.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Meng</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Wen</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J. L.</given-names>
</string-name>, … <string-name>
<surname>Liao</surname>, <given-names>W. P.</given-names>
</string-name> (<year>2013</year>). <article-title>Novel PRRT2 mutations in paroxysmal dyskinesia patients with variant inheritance and phenotypes</article-title>. <source xml:lang="en"/>Genes, Brain, and Behavior, <volume>12</volume>, <fpage>234</fpage>–<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1111/gbb.12008</pub-id>.</mixed-citation>
</ref>
<ref id="brb31134-bib-0018">
<mixed-citation id="brb31134-cit-0018" publication-type="journal">
<string-name>
<surname>Olson</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Shen</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Avallone</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Sheidley</surname>, <given-names>B. R.</given-names>
</string-name>, <string-name>
<surname>Pinsky</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Bergin</surname>, <given-names>A. M.</given-names>
</string-name>, … <string-name>
<surname>Poduri</surname>, <given-names>A.</given-names>
</string-name> (<year>2014</year>). <article-title>Copy number variation plays an important role in clinical epilepsy</article-title>. <source xml:lang="en"/>Annals of Neurology, <volume>75</volume>, <fpage>943</fpage>–<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24178</pub-id>.<pub-id pub-id-type="pmid">24811917</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0019">
<mixed-citation id="brb31134-cit-0019" publication-type="journal">
<string-name>
<surname>Silveira‐Moriyama</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Gardiner</surname>, <given-names>A. R.</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>King</surname>, <given-names>M. D.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rakshi</surname>, <given-names>K.</given-names>
</string-name>, … <string-name>
<surname>Kurian</surname>, <given-names>M. A.</given-names>
</string-name> (<year>2013</year>). <article-title>Clinical features of childhood‐onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations</article-title>. <source xml:lang="en"/>Developmental Medicine and Child Neurology, <volume>55</volume>, <fpage>327</fpage>–<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1111/dmcn.12056</pub-id>.<pub-id pub-id-type="pmid">23363396</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0020">
<mixed-citation id="brb31134-cit-0020" publication-type="journal">
<string-name>
<surname>Termsarasab</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Reiner</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Mei</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Scott</surname>, <given-names>S. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Frucht</surname>, <given-names>S. J.</given-names>
</string-name> (<year>2014</year>). <article-title>Paroxysmal kinesigenic dyskinesia caused by 16p11.2 microdeletion</article-title>. <source xml:lang="en"/>Tremor and Other Hyperkinetic Movements, <volume>4</volume>, <fpage>274</fpage>
<pub-id pub-id-type="doi">10.7916/D8N58K0Q</pub-id>.<pub-id pub-id-type="pmid">25667815</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0021">
<mixed-citation id="brb31134-cit-0021" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>H. X.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>H. F.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>G. L.</given-names>
</string-name>, <string-name>
<surname>Wen</surname>, <given-names>X. D.</given-names>
</string-name>, &amp; <string-name>
<surname>Wu</surname>, <given-names>Z. Y.</given-names>
</string-name> (<year>2016</year>). <article-title>Mutation analysis of MR‐1, SLC2A1, and CLCN1 in 28 PRRT2‐negative paroxysmal kinesigenic dyskinesia patients</article-title>. <source xml:lang="en"/>Chinese Medical Journal, <volume>129</volume>, <fpage>1017</fpage>–<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.4103/0366-6999.180529</pub-id>.<pub-id pub-id-type="pmid">27098784</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0022">
<mixed-citation id="brb31134-cit-0022" publication-type="journal">
<string-name>
<surname>Weber</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kohler</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Neubauer</surname>, <given-names>B.</given-names>
</string-name>, &amp; <string-name>
<surname>Muller</surname>, <given-names>U.</given-names>
</string-name> (<year>2013</year>). <article-title>Benign infantile convulsions (IC) and subsequent paroxysmal kinesigenic dyskinesia (PKD) in a patient with 16p11.2 microdeletion syndrome</article-title>. <source xml:lang="en"/>Neurogenetics, <volume>14</volume>, <fpage>251</fpage>–<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1007/s10048-013-0376-7</pub-id>.<pub-id pub-id-type="pmid">24100940</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0023">
<mixed-citation id="brb31134-cit-0023" publication-type="journal">
<string-name>
<surname>Weiss</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Shen</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Korn</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Arking</surname>, <given-names>D. E.</given-names>
</string-name>, <string-name>
<surname>Miller</surname>, <given-names>D. T.</given-names>
</string-name>, <string-name>
<surname>Fossdal</surname>, <given-names>R.</given-names>
</string-name>, … <string-name>
<surname>Autism</surname>, <given-names>C.</given-names>
</string-name> (<year>2008</year>). <article-title>Association between microdeletion and microduplication at 16p11.2 and autism</article-title>. <source xml:lang="en"/>New England Journal of Medicine, <volume>358</volume>, <fpage>667</fpage>–<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa075974</pub-id>.<pub-id pub-id-type="pmid">18184952</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0024">
<mixed-citation id="brb31134-cit-0024" publication-type="journal">
<string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mahrt</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Foley</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Portmann</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Dolmetsch</surname>, <given-names>R. E.</given-names>
</string-name>, … <string-name>
<surname>Crawley</surname>, <given-names>J. N.</given-names>
</string-name> (<year>2015</year>). <article-title>16p11.2 deletion syndrome mice display sensory and ultrasonic vocalization deficits during social interactions</article-title>. <source xml:lang="en"/>Autism Research, <volume>8</volume>, <fpage>507</fpage>–<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1465</pub-id>.<pub-id pub-id-type="pmid">25663600</pub-id></mixed-citation>
</ref>
<ref id="brb31134-bib-0025">
<mixed-citation id="brb31134-cit-0025" publication-type="journal">
<string-name>
<surname>Youn</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>J. S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Roh</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Ki</surname>, <given-names>C. S.</given-names>
</string-name>, &amp; <string-name>
<surname>Choa</surname>, <given-names>J. W.</given-names>
</string-name> (<year>2014</year>). <article-title>Clinical manifestations in paroxysmal kinesigenic dyskinesia patients with proline‐rich transmembrane protein 2 gene mutation</article-title>. <source xml:lang="en"/>Journal of Clinical Neurology, <volume>10</volume>, <fpage>50</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.3988/jcn.2014.10.1.50</pub-id>.<pub-id pub-id-type="pmid">24465263</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>